Investigating mutations in RUNX1 and their role in acute myeloid leukemia
Assessing lineage infidelity, oncogenic cooperativity and dependency in RUNX1-mutant acute myeloid leukemia
This study is looking at how changes in the RUNX1 gene might make acute myeloid leukemia (AML) harder to treat with chemotherapy, especially for patients who aren't responding well to treatment, and it hopes to find new ways to understand and fight this type of leukemia.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10895514 on NIH RePORTER |
What this research studies
This research focuses on understanding how mutations in the RUNX1 gene contribute to acute myeloid leukemia (AML), particularly in patients who show resistance to chemotherapy. By using advanced genetic models, the study aims to explore the mechanisms behind lineage infidelity, which is when leukemia cells deviate from their expected development path. The researchers will also examine how these mutations interact with other genetic changes, such as NRAS mutations, to promote leukemia progression. This work could lead to new insights into the biology of AML and potential therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have RUNX1 mutations.
Not a fit: Patients with acute myeloid leukemia who do not have RUNX1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with RUNX1-mutant acute myeloid leukemia.
How similar studies have performed: Previous research has shown that understanding genetic mutations in leukemia can lead to significant advancements in treatment, suggesting that this approach has the potential for success.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Xiao, Wenbin — Sloan-Kettering Inst Can Research
- Study coordinator: Xiao, Wenbin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.